Ornithine Alpha-Ketoglutarate

Also indexed as: OKG

What is it?

The amino acids ornithine and glutamine are combined to form ornithine alpha-ketoglutarate (OKG).

OKG has been shown to improve protein retention, wound repair, and immune function in hospitalised patients partly by increasing levels of growth-promoting (anabolic) hormones such as insulin and growth hormone.1 In a large, well-controlled trial,2 nonhospitalized elderly people benefited from 10 grams per day of OKG as they recovered from various illnesses or surgery, showing improved appetite, weight gain, muscle growth, reduced need for medical care, and improved quality of life. No studies on muscle growth in athletes using OKG have been published.

Where is it found?

Although the amino acids that comprise OKG are present in protein foods such as meat and poultry and fish, the OKG compound is found only in supplements.

OKG has been used in connection with the following condition (refer to the individual health concern for complete information):

Rating Health Concerns
2Stars

Wound healing
3Stars Reliable and relatively consistent scientific data showing a substantial health benefit.
2Stars Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
1Star For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support and/or minimal health benefit.

Who is likely to be deficient?

A deficiency of OKG has not been reported.

How much is usually taken?

Optimal levels remain unknown, though 10 grams per day has been used in clinical trials.

Are there any side effects or interactions?

No side effects have been reported with the use of OKG.

No clear interactions between OKG and other nutrients have been established.

At the time of writing, there were no well-known drug interactions with Ornithine Alpha-Ketoglutarate.

References

1. Le Boucher J, Cynober LA. Ornithine alpha-ketoglutarate: the puzzle. Nutrition 1998;14:870–3 [review].

2. Brocker P, Vellas B, Albarede J, et al. A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Aging 1994;23:303–6.